logo
  

Integra LifeSciences Boosts FY21 Outlook - Quick Facts

While reporting financial results for the second quarter on Wednesday, medical technology company Integra LifeSciences Holdings Corp. (IART) raised its adjusted earnings and revenue guidance for the full-year 2021, based on better than expected second quarter financial performance. The company also issued outlook for the third quarter.

For fiscal 2021, the company now projects adjusted earnings in a range of $2.98 to $3.05 per share on revenues between $1.540 billion and $1.550 billion, with revenue growth of 12 to 13 percent and organic revenue growth of 13 to 14 percent.

The company expected adjusted earnings in the range of $2.86 to $2.93 per share on revenues between $1.525 billion and $1.535 billion, with revenue growth of 11 to 12 percent and organic revenue growth of 12 to 13 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.92 per share on revenues of $1.53 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, the company expects adjusted earnings in a range of $0.71 to $0.74 per share on revenues between $382 million and $389 million, with revenue growth of 3 to 5 percent and organic revenue growth of 5 to 7 percent.

The Street is looking for earnings of $0.74 per share on revenues of $389.25 million for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022. Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and...
RELATED NEWS
Follow RTT